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ABSTRACT
Introduction: Breast cancer has a lifetime incidence of
one in eight women. Over the past three decades there
has been a move towards breast conservation and a
focus on aesthetic outcomes while maintaining
oncological safety. For some patients, mastectomy
is the preferred option. There is growing interest in
the potential use of nipple sparing mastectomy
(NSM). However, oncological safety remains
unproven, and the benefits and indications have not
been clearly identified. The objective of this systematic
review will be to determine the safety and efficacy of
NSM as compared with skin sparing mastectomy
(SSM).
Methods and analysis: All original comparative
studies including; randomised controlled trials, cohort
studies and case–control studies involving women
undergoing either NSM or SSM for breast cancer will be
included. Outcomes are primary—relating to
oncological outcomes and secondary—relating to
clinical, aesthetic, patient reported and quality of life
outcomes. A comprehensive electronic literature search,
designed by a search specialist, will be undertaken. Grey
literature searches will also be conducted. Eligibility
assessment will occur in two stages; title and abstract
screening and then full text assessment. Each step will
be conducted by two trained teams acting
independently. Data will then be extracted and stored in
a database with standardised extraction fields to
facilitate easy and consistent data entry. Data analysis
will be undertaken to explore the relationship between
NSM or SSM and preselected outcomes, heterogeneity
will be assessed using the Cochrane tests.
Ethics and dissemination: This systematic review
requires no ethical approval. It will be published in a
peer-reviewed journal. It will also be presented at
national and international conferences. Updates of the
review will be conducted to inform and guide healthcare
practice and policy.
BACKGROUND
Breast cancer epidemiology
Breast cancer is the most common cancer in
the UK and accounts for 31% of all new
cancer cases, with a lifetime incidence of 1
in 8 in women.1 Fifty thousand women are
diagnosed with breast cancer each year,
16 000 of whom undergo mastectomy. There
are also approximately 12 000 deaths from
the disease.2 Similarly, in the USA, the
National Cancer Institute predicted 232 340
new cases and 39 620 deaths from breast
cancer in 2013 with over 96 000 undergoing
breast reconstruction following surgery.3
The history of mastectomy
Halsted’s radical mastectomy had been the
standard of care for patients since its incep-
tion in 1894 up to the 1960s. Patey described
the modiﬁed radical mastectomy, which
achieved a local recurrence rate of 10% after
10 years.4 Skin sparing mastectomy (SSM)
was ﬁrst described in 1991 by Toth and
Lappert; it involves removing the entire
breast and nipple-areola complex (NAC)
while maintaining the skin envelope and the
native inframammary fold (IMF).5 A subse-
quent meta-analysis by Lanitis et al6 in 2010
found that local recurrence rates after SSM
are equivalent to those after modiﬁed radical
mastectomy (MRM).
The advent of nipple sparing mastectomy
What are the pros and cons of nipple preser-
vation? The fundamental reason for
Strengths and limitations of this study
▪ Multidisciplinary team conducting a non-
commercial systematic review and meta-analysis
in an important topic.
▪ Team has specific experience and training in
conducting meta-analysis and systematic review.
▪ Potential lack of high quality studies limiting the
ability to conduct robust meta-analysis.
▪ Potential reporting bias within the existing
literature.
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attempting nipple preservation is aesthetics, with studies
reporting psychological beneﬁts and improved patient
satisfaction.7 The nipple is one of the key deﬁning visual
features of a breast. With removal of the NAC, the point
in the proﬁle at which the most natural convexity occurs
is lost.8 Preserving the NAC also eliminates the need for
staged nipple reconstruction and areola tattooing, after
which there can be loss of projection and fading over
time, respectively.
Traditionally mastectomy has included resection of the
NAC together with the gland. The concern being that
the NAC may harbour occult tumour cells. Indeed, large
trials have shown the NAC to be involved in 5–12% of
cases. The earliest report of nipple sparing mastectomy
(NSM) came from Hinton in 1984, who reported that
NSM achieved comparable local recurrence rates and sur-
vival to that of MRM.9 However, the technique did not
achieve widespread use due to oncological concerns at
the time, and these concerns persist still.10 11 Previously,
NSM was approached cautiously in the context of patients
who had received neoadjuvant chemotherapy, but recent
data suggest this may be safe.12 Similar concerns were
raised over the oncological safety of breast conserving
surgery for small tumours until Veronesi et al published
their seminal randomised controlled trial (RCT) with
20-year follow-up showing equivalent oncological out-
comes to mastectomy.12 The treatment of breast cancer
has become more nuanced over the past few decades,
and a gradual process of systematic improvement has
taken place to improve outcomes, both oncologically and
aesthetically.14 Treatments are tailored to individuals and
care is directed through multidisciplinary teams. So does
therapeutic NSM have an oncologically safe role in care-
fully selected patients?
What have we learnt from prior systematic reviews?
Table 1 below summarises recent systematic reviews
assessing NSM.
The quality of the previous systematic reviews is
assessed in table 2 below using the validated assessment
tool ‘Assessment of Multiple Systematic Reviews’
(AMSTAR).16–18
Why is it important to do this systematic review?
NSM is an active research front. A basic search using the
database Scopus for ‘nipple sparing mastectomy’ reveals
how research and interest in this area has increased in
recent years (ﬁgure 1):
Table 1 Prior reviews of nipple sparing mastectomy
Review
Databases included and
years searched
Studies/patients
included Key findings
Zhang et al
201518
PubMed, 1978–2014 27 studies, 7971
patients
‘Owing to the statistical heterogeneity detected with
certain parameters, further investigations to confirm their
association with nipple involvement [NI] will be needed.
Patients with one or more risk factors such as centrally
located tumours; higher tumour stage; large tumours; ER
negative/PR negative/HER positive status and
associated DCIS have higher risk of NI.
Taking these factors into consideration comprehensively
may help with decision-making process for NSM.’
Piper et al
201319
MEDLINE and Cochrane
databases, inception to Nov
2011
27 studies, 3331
mastectomies
‘Review of oncological outcomes in the 10 studies
(representing 1148 mastectomies) with documented
mean/median follow-up of 2 years demonstrated an
overall locoregional recurrence rate of 2.8%.
Ischaemic complications involving the NAC were
reported in 24 studies (representing 3091
mastectomies), with 9.1% of cases reported to have
some degree of NAC necrosis and 2.0% of cases
complicated by complete necrosis leading to NAC loss.
Sixteen studies (representing 2213 mastectomies)
reported rates of skin flap necrosis, which occurred in
9.5% of cases.’
Endara et al
201320
PubMed and Ovid
databases, 1970 to 1
January 2013
48 studies, 5166
patents
‘Nipple sparing mastectomy appears to be an
oncologically safe option for properly selected patients,
with low rates of locoregional and distant metastasis.
Overall complication and nipple necrosis rates are
affected by incision location and reconstruction method.’
De La Cruz
et al 201521
MEDLINE, Scopus, Google
Scholar from 1967-Jan 2015
20 studies, 5594
patients
Adverse oncological outcomes of NSM in carefully
selected women with early stage breast cancer were not
detected.
DCIS, ductal carcinoma in situ; ER, estrogen-receptor; HER, human epidermal growth factor receptor; NAC, nipple-areola complex; NI, nipple
involvement; NSM, nipple sparing mastectomy; PR, progesterone receptor.
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Since the most recent systematic review of NSM con-
cluded its search in January 2014, there have been over
100 more articles published in this area (ﬁgure 1).13 A
new systematic review is needed to update our under-
standing of this rapidly evolving area and potentially
answer the questions previous studies have failed to.
OBJECTIVES
Our objective is to perform a comprehensive systematic
review of NSM with a particular focus on safety and
efﬁcacy.
Primary objectives
In the context of using NSM for women with breast
cancer, we aim to determine its:
1. Oncological outcomes
2. Clinical outcomes
3. Aesthetic outcomes
4. Patient reported outcomes
5. Quality of life outcomes
Secondary objectives
1. To determine the contraindications for the procedure.
2. To help reﬁne patient selection for the procedure.
METHODS
This review will be conducted in line with the recommen-
dations speciﬁed in the Cochrane Handbook for inter-
vention reviews V.5.1.0 and is AMSTAR compliant.22 It
will be reported in line with the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement.23 This protocol has been devel-
oped a priori and registered on the Research Registry
UIN: reviewregistry29 (http://www.researchregistry.com).
Criteria for selecting studies for this review
The following inclusion and exclusion criteria were
explicitly formulated to minimise heterogeneity and
address the research questions asked.
Types of studies
All comparative studies including: RCTs; cohort and
case–control studies will be included. Hence, levels of
Table 2 Quality of prior systematic review according to AMSTAR
AMSTAR Criterion
Zhang et al
201518
Piper et al
201319
Endara et al
201320
De La Cruz
et al 201521
1. Was an ‘a priori’ design provided? NO NO NO NO
2. Was there duplicate study selection and data
extraction?
NO (only data
extraction)
NO YES YES
3. Was a comprehensive literature search
performed?
NO (single
database only)
NO (only two
databases)
NO (only two
databases)
YES
4. Was the status of publication (i.e, grey
literature) used as an inclusion criterion?
NO NO NO NO
5. Was a list of studies (included and excluded)
provided?
NO
(included only)
NO
(included only)
NO NO
6. Were the characteristics of the included studies
provided?
YES YES YES YES
7. Was the scientific quality of the included
studies assessed and documented?
NO NO YES NO
8. Was the scientific quality of the included
studies used appropriately in formulating
conclusions?
NO NO YES YES
9 Were the methods used to combine the findings
of studies appropriate?
YES NA YES YES
10. Was the likelihood of publication bias
assessed?
YES NO NO NO
11. Was the conflict of interest stated? YES YES YES YES
Total 4 2 6 6
NA, not available.
Figure 1 Number of articles published per year and indexed
by Scopus under the search term ‘nipple sparing
mastectomy’.
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evidence 1–3, as deﬁned by the Oxford Centre for
Evidence-Based Medicine with exclusion of single group
cohorts, case series, case reports and expert opinion.24
Only articles which mention one or more of the out-
comes of interest will be included. Duplicate studies will
be excluded as will: cost-effectiveness studies and those
where original data are not reported, or purely technical
descriptions.
Types of participants
Women undergoing mastectomy for breast cancer. Male
and transgender cases will be excluded.
Types of interventions
NSM, which involves the removal of all glandular breast
tissue and preservation of the native skin envelope, IMF
and nipple. Subcutaneous mastectomy will be excluded.
Types of comparators
Where possible, the intervention will be compared with
skin sparing mastectomy—where the nipple-areola
complex and the gland are removed but the skin and
inframammary crease are preserved.
Types of outcome measures
Primary outcomes include overall survival and local
recurrence rate in the follow-up period. Secondary out-
comes include: clinical complications such as NAC or
skin ﬂap necrosis, haematoma, seroma, infection and
readmission to hospital. Also aesthetic outcomes as
judged by the relevant instrument used in the study,
patient reported outcomes (such as patient satisfaction)
and quality of life outcomes such as psychological well-
being, impact on body image, relationships and sexual-
ity, using instruments like EQ-5D.
Search methods for identification of studies
Electronic searches
The following electronic databases will be searched from
inception to 31 December 2015: MEDLINE, EMBASE,
SciELO, The Cochrane Library, including the Cochrane
Database of Systematic Reviews (CDSR), Cochrane
Central Register of Controlled Trials (CENTRAL),
Database of Abstracts of Reviews of Effect (DARE), the
Cochrane Methodology Register, Health Technology
Assessment Database, the NHS Economic Evaluation
Databases and Cochrane Groups, ClinicalTrials.gov, the
WHO International Clinical Trials Registry Platform.
Search terms and keywords
A search will be constructed and conducted by an infor-
mation specialist experienced in systematic review, using
appropriate keywords in the English language combined
with Boolean logical operators. The search strategy for
MEDLINE is shown below as an example (table 3):
Searches will be translated to the appropriate syntax
of other databases, free text and the relevant database
thesaurus terms will be used.
Reports will not be excluded based on their publication
status. The search will not be limited by language and
non-English full texts will proceed to title and abstract
screening (since the abstract will be in English). If the full
paper is required authors will be contacted to provide a
translated copy. If this is not possible, native language
speaker translation will be undertaken. Finally, Google
Translate (Google, Mountain View, California, USA) will
be used.25 It has been recognised as an approach to poten-
tially minimise language bias in systematic reviews.26
Searching other resources
Grey literature searches will include a search of Open
Grey (http://www.opengrey.eu). In addition, references
of all included papers and prior systematic reviews will
be searched for any relevant studies that were not
already captured through our search.
Identification and selection of studies
Studies identiﬁed through the electronic and manual
searches will be listed within a Microsoft Excel 2011 data-
base and duplicates excluded (Microsoft, Redmond,
Washington, USA). The selection of articles will be con-
ducted in two stages by individuals trained in the process
and who will be given detailed eligibility instructions:
1. Titles and abstracts will be screened by two research-
ers. Discrepancies will be resolved through discus-
sion. If any doubt about inclusion exists, the article
will proceed to the next stage.
2. The full-text of the articles selected above will be
downloaded and further assessed for inclusion by two
researchers. Discrepancies will be resolved by consen-
sus. If this is not possible, one of the senior authors
will be asked to make a ﬁnal decision as to inclusion.
Where required, authors will be contacted to clarify inclu-
sion, data overlap and data. Once ﬁnal decisions on study
inclusion have been made, data will be extracted from
included studies.
Data extraction, collection and management
Data extraction will be performed independently by two
teams of researchers. Discrepancies will then be resolved
by consensus. Final decisions on data will be made by a
senior author.
Table 3 Literature search strategy
# Search Results
1 exp Breast Neoplasms/su (Surgery) 31 262
2 exp Mastectomy/ 24 336
3 (breast* adj2 (surg* or reconstruct*)].ti,ab. 15 404
4 mastectom*.ti,ab. 16 370
5 1 or 2 or 3 or 4 50 022
6 [(nipple* or areola* or nac) adj3 (spare? or
sparing or preserv* or reposition*)].ti,ab.
513
7 5 and 6 424
8 Nipples/and Organ Sparing Treatment/ 21
9 7 or 8 426
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Data will be extracted into a standardised Microsoft
Excel 2011 (Microsoft, Redmond, Washington, USA)
database. The following data will be extracted:
▸ Author names, countries and year of publication
▸ Study design and level of evidence
▸ Conﬂicts of interest and funding
▸ Number of participants
▸ Number of breasts treated
▸ Intention—risk reducing or therapeutic
▸ Age of participants
▸ Oncological parameters—type of cancer (invasive or
in situ), grade, stage, axillary nodal status, hormone
receptor status (ER, PR), HER2 status, size of tumour,
tumour-nipple distance, solitary or multifocal or mul-
ticentric and presence of lymphovascular invasion.
▸ Prior adjuvant radiotherapy
▸ Prior neoadjuvant or adjuvant chemotherapy
▸ Previous breast surgery
▸ Technical details—incision used and reconstruction
performed
▸ Median follow-up duration
▸ Loss to follow-up expressed as a percentage
▸ Outcomes—primary and secondary as described above
Assessment of risk of bias in included studies
We will use the Cochrane Risk of Bias Tool for RCTs.27
This examines the following domains: sequence
generation; allocation concealment; blinding of partici-
pants; personnel and outcome assessors; incomplete
outcome data; selective outcome reporting and other
sources. For Non-Randomised studies we will use the rele-
vant Cochrane Risk of Bias Assessment Tool
ACROBAT-NRSI.28
We will compare study protocols with ﬁnal papers
where possible. Key missing information across all study
types will be presented.
Assessment of publication bias
We will analyse funnel plot asymmetry to determine if there
is a deﬁciency of reports of negative study outcomes.29
Strategy for data synthesis and statistical analysis
Outcomes of interest will be presented appropriately. When
possible, NSM and SSM will be compared. Using Review
Manager V.5.2.6 (RevMan), an assessment of heterogeneity
in comparative studies will be made (Copenhagen: The
Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan) Version 5.2. 2012). If high as
deﬁned by the I2 statistic (I2>50%), meta-analysis will be
performed using a random effects model, otherwise a ﬁxed
effects model will be used.26
Subgroup analysis
We will perform an additional analysis to see if particular
oncological proﬁles are associated with better outcomes
post-NSM.
Dissemination
Based on the results of this systematic review, independ-
ent analysis and recommendations will be made to clini-
cians, researchers, plastic and breast surgical societies
and policy makers. Authors of guidelines relating to
oncological breast surgery will be informed of the results
directly. It will be published in a peer-reviewed journal
and presented at national and international confer-
ences. A lay summary and short summary will be disse-
minated to the appropriate audiences by email.
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